Home → Treatment & Side Effects → Planning Your Treatment → Ask-the-Expert Conferences: Treatment Issues → August 2007: Managing Ongoing Medications → Safety of estrogen ring on Arimidex?

Safety of estrogen ring on Arimidex?

Page last modified on: October 13, 2008

Question from SalH: I am on Arimidex and find intercourse extremely painful due to dryness. How safe is the estrogen ring?: Answer —Patricia Ganz, M.D.: Using vaginal estrogen even in low dose may complicate the management of your treatment on Arimidex. We have felt comfortable using vaginal estrogen supplements such as Vagifem or Estring for women who are on tamoxifen because tamoxifen blocks the uptake of any blood level of estrogen that could get into breast cancer cells. However, the strategy of using Arimidex and the other aromatase inhibitors is to lower the estrogen level as low as possible, down to nearly zero. If you use a vaginal estrogen preparation, even in these low doses, it will raise the estrogen level in the blood so that you may be counteracting the benefits of the aromatase inhibitor. I am currently measuring estradiol blood levels in my patients who are using vaginal estrogen because I want to make sure it doesn't elevate the levels. So you might be defeating the purpose of the aromatase inhibitor. If this were to be used, it would have to be used with great caution and with monitoring. You can also use other non-estrogen preparations. One is Replens, a vaginal moisturizer used twice a week. In a randomized trial that we did several years ago, we found that women's vaginal symptoms improved and their sexual functioning also improved. You can also use a preparation as a lubricant at the time of sexual intercourse, which may also help, and there is a variety available at the drug store. You should also know that vaginal dryness is a common symptom of women as they age, so what you are experiencing is an exaggeration of the symptoms that women in postmenopausal years experience.

On Wednesday, August 15, 2007, the Ask-the-Expert Online Conference was called Managing Ongoing Medications. Patricia Ganz, M.D. and moderator Lillie Shockney, R.N., B.S., M.A.S. answered your questions about staying on track with breast cancer medications you have to take on a regular basis.

The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.

A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.

Was this resource helpful?

Yes No

Thank you for your input!

Email Updates

Stay informed about current research, online events, and more.

Meet the Experts

Patricia A. Ganz, M.D. is a medical oncologist and a professor in the schools of medicine and public health at UCLA, and is director of the division of cancer prevention and control research at the Jonsson Comprehensive Cancer Center there.

Lillie Shockney, RN., BS., M.A.S. Lillie Shockney, R.N., B.S., M.A.S. is the administrative director of the Johns Hopkins Avon Foundation Breast Center.